Novel matrix sustained-release tablet and preparation method thereof

A skeleton slow-release material and slow-release tablet technology, applied in the field of medicine, can solve the problems of accelerated drug release, slow release rate, single release mechanism, etc., and achieve the effect of increasing the release rate and uniform drug release rate

Inactive Publication Date: 2011-01-05
北京天衡药物研究院有限公司
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, venlafaxine hydrochloride, due to its exceptionally excellent water solubility (measured solubility can reach 1.5g/ml), even when the sustained-release material accounts for 60% of the weight of the entire tablet, the 2-hour release is still close to 40%. , for a preparation that requires 24h sustained release, it is obviously faster
[0012] 2. The release mechanism is single, and the release process control method is lacking: the release characteristics of the hydrophilic gel matrix of general water-soluble drugs are diffusion + erosion type, and they are of this type throughout the drug release process, so the drug is in the first-order or false state. First-order rate release, that is, the release rate decreases significantly with time, and the release rate is quite slow at the end of the release period
Since the main drugs are released in the first half of the entire release time (>70%), and most of the drugs are eliminated at the first-order rate, the rate of drug elimination from the peak concentration is much faster than that of matrix sustained-release tablets. The release rate of the drug in the later period, and thus unable to maintain the effective blood drug concentration in the later period of drug administration
For example, the commercially available venlafaxine hydrochloride sustained-release tablets release less than 10% of the drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel matrix sustained-release tablet and preparation method thereof
  • Novel matrix sustained-release tablet and preparation method thereof
  • Novel matrix sustained-release tablet and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Example 1 Venlafaxine Hydrochloride Ordinary Matrix Sustained Release Tablet

[0082] 1) Prescription composition

[0083] Composition Dosage (1000 tablets)

[0084] Venlafaxine hydrochloride 84.9g

[0085] Hypromellose K4M 70g

[0086] Hypromellose K15M 50g

[0087] Micronized silica gel 50g

[0088] Stearic acid 30g

[0089] 10% PVPK3085% ethanol appropriate amount

[0090] Magnesium stearate 3g

[0091] 2) Preparation process:

[0092] (1) Take the prescription amount of venlafaxine hydrochloride, hydroxypropyl methyl cellulose K4M, hydroxypropyl methyl cellulose K15M, micro powder silica gel and stearic acid and mix well;

[0093] (2) 10% PVP K3085% ethanol solution made of soft material, passed through a 20-mesh sieve to make wet granules;

[0094] (3) Dry at 40°C, and pass through a 20-mesh sieve;

[0095] (4) Add the prescribed amount of magnesium stearate and mix well.

[0096] Press the prepared granules in a rotary tablet press to obtain venlafaxine hydrochloride sustained-releas...

Embodiment 2

[0102] Example 2 Venlafaxine Hydrochloride Double-layer Sustained-Release Tablets Containing Retention Layer:

[0103] 1) Prescription composition

[0104] Medicinal layer:

[0105] Composition Dosage (1000 tablets)

[0106] Venlafaxine hydrochloride 84.9g

[0107] Hypromellose K4M 70g

[0108] Hypromellose K15M 50g

[0109] Micronized silica gel 50g

[0110] Stearic acid 30g

[0111] 10% PVPK3085% ethanol appropriate amount

[0112] Magnesium stearate 3g

[0113] Blocking layer:

[0114] Composition Dosage (1000 tablets)

[0115] Hypromellose K4M 10g

[0116] Hypromellose K100 20g

[0117] Micronized silica gel 15g

[0118] Lactose 35g

[0119] 10% PVPK3085% ethanol appropriate amount

[0120] Magnesium stearate 3g

[0121] 2) Preparation process:

[0122] Medicinal layer:

[0123] (1) Take the prescription amount of venlafaxine hydrochloride, hydroxypropyl methyl cellulose K4M, hydroxypropyl methyl cellulose K15M, micro powder silica gel and stearic acid and mix well;

[0124] (2) 10% PVPK3085% ethano...

Embodiment 3

[0141] Example 3 Venlafaxine Hydrochloride Double-layer Sustained-Release Tablets Containing Retention Layer:

[0142] 1) Prescription composition

[0143] Medicinal layer:

[0144] Composition Dosage (1000 tablets)

[0145] Venlafaxine hydrochloride 84.9g

[0146] Hypromellose K4M 70g

[0147] Hypromellose K15M 50g

[0148] Micronized silica gel 50g

[0149] Stearic acid 30g

[0150] 10% PVPK3085% ethanol appropriate amount

[0151] Magnesium stearate 3g

[0152] Blocking layer:

[0153] Composition Dosage (1000 tablets)

[0154] Hypromellose K4M 30g

[0155] Micronized silica gel 10g

[0156] Stearic acid 10g

[0157] 10% PVPK3085% ethanol appropriate amount

[0158] Magnesium stearate 3g

[0159] 2) Preparation process:

[0160] Medicinal layer:

[0161] (1) Take the prescription amount of venlafaxine hydrochloride, hydroxypropyl methyl cellulose K4M, hydroxypropyl methyl cellulose K15M, micro powder silica gel and stearic acid and mix well;

[0162] (2) 10% PVP K3085% ethanol solution made of soft ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a novel long-acting sustained-release preparation and a preparation method thereof, in particular to a matrix sustained-release tablet with a controlled retardant layer and a preparation method thereof. The invention enables the matrix sustained-release tablet to be changed from the traditional single-layer tablet core structure to a double-layer structure including a drug containing layer and the controlled retardant layer by adding the controlled retardant layer to the structure of the traditional matrix sustained-release tablet, can also control the time of the retardant layer playing a retardant role by controlling the dissolving or corroding time of the retardant layer through predesign, very efficiently control the drug release and reduce the burst release and the late residuals, thereby obtaining excellent release effect.

Description

Technical field [0001] The invention belongs to the field of medicine, and relates to a novel matrix sustained-release tablet, in particular to a matrix sustained-release tablet with a controllable retardation layer. Background technique [0002] After nearly 50 years of development, oral drug sustained-release and controlled-release pharmaceutical preparations have become an important direction for the development of domestic and foreign pharmaceutical products. At present, there are more than 200 varieties of such preparations on the market abroad with more than 500 specifications. In 2008, the global market for oral sustained and controlled release preparations exceeded US$30 billion. [0003] The preferred dosage form of sustained-release pharmaceutical preparations is tablets. At present, the most widely used in the world is the use of hydrophilic gel matrix tableting technology to make hydrophilic gel matrix tablets. When producing such sustained-release tablets, the activ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/24A61K9/28A61K47/12A61K47/14A61K47/32A61K47/34A61K47/36A61K47/38A61K47/44A61K47/10
Inventor 姜庆伟刘全志杨文斌梁希
Owner 北京天衡药物研究院有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products